Singapore markets closed

Straits Times Index
3,296.89
+4.20(+0.13%)
S&P 500
5,056.53
+38.14(+0.76%)
Dow
38,139.50
+236.21(+0.62%)
Nasdaq
15,605.48
-52.34(-0.33%)
Bitcoin USD
58,771.12
+1,070.89(+1.86%)
CMC Crypto 200
1,262.26
-8.48(-0.67%)

REGN Jan 2026 800.000 call

OPR - OPR Delayed price. Currency in USD

Add to watchlist

274.13

0.00

(0.00%)

As of 12:02PM EDT. Market open.

GuruFocus.com
Regeneron Pharmaceuticals Inc (REGN) Q1 2024 Earnings: Challenges and Opportunities Amidst ...
First Quarter Results Show Revenue Decline but Strong Dupixent and Libtayo Sales Growth
Simply Wall St.
Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...
GlobeNewswire
Regeneron Reports First Quarter 2024 Financial and Operating Results
First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP dil